Globalisation of clinical trials and ethics of benefit sharing

Raffaella Ravinetto; Pier Davide Guenzi; Pierre Massat; Gianluca Gaidano

doi:10.1016/S2352-3026(14)00004-0

Globalisation of clinical trials and ethics of benefit sharing

Raffaella Ravinetto
, Pier Davide Guenzi
, Pierre Massat
, Gianluca Gaidano

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Commento

Lingua originale	Inglese
pagine (da-a)	e54-e56
Rivista	The Lancet Haematology
Volume	1
Numero di pubblicazione	2
DOI	https://doi.org/10.1016/S2352-3026(14)00004-0
Stato di pubblicazione	Pubblicato - 2014

Accesso al documento

10.1016/S2352-3026(14)00004-0

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{1a33cbe164fe4b2990e0a096cb98c19f,

title = "Globalisation of clinical trials and ethics of benefit sharing",

author = "Raffaella Ravinetto and Guenzi, \{Pier Davide\} and Pierre Massat and Gianluca Gaidano",

note = "Funding Information: RR, PDG, and PM have nothing to disclose. GG reports personal fees outside the submitted work from Roche, Janssen, Amgen, Novartis, Bristol-Myers Squibb, and grants from Celgene.",

year = "2014",

doi = "10.1016/S2352-3026(14)00004-0",

language = "English",

volume = "1",

pages = "e54--e56",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Globalisation of clinical trials and ethics of benefit sharing

AU - Ravinetto, Raffaella

AU - Guenzi, Pier Davide

AU - Massat, Pierre

AU - Gaidano, Gianluca

N1 - Funding Information: RR, PDG, and PM have nothing to disclose. GG reports personal fees outside the submitted work from Roche, Janssen, Amgen, Novartis, Bristol-Myers Squibb, and grants from Celgene.

PY - 2014

Y1 - 2014

UR - https://www.scopus.com/pages/publications/84922120783

U2 - 10.1016/S2352-3026(14)00004-0

DO - 10.1016/S2352-3026(14)00004-0

M3 - Comment/debate

SN - 2352-3026

VL - 1

SP - e54-e56

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 2

ER -